All In Biotech

Drug Trial Radar · NCT06945445

Study of SLN12140 in Healthy Adult Participants

A Phase 1, Randomized, Double-blind, Placebo-controlled, Single Ascending Dose and Multiple Dose Study of SLN12140 Administered Subcutaneously or Intravenously in Healthy Adult Volunteers

Last checked: Nov 19, 2026Latest source record: Apr 25, 2025 (this record)Source: ClinicalTrials.govMethods & limitations

Not yet recruiting

Status

Not yet recruiting

Enrollment

56

Planned (sponsor's estimate)

Start

Apr 2025

Primary completion

May 2026

Study completion Jun 2026

Sponsor

Lead sponsor
Linno Pharmaceuticals, Inc.Industry
Sponsor type
Industry
First posted
Apr 25, 2025

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 1
Allocation
Randomized
Model
Parallel
Masking
Triple (participant, care provider, investigator)
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 18 days, up to 65 days
Healthy volunteers
Yes

Summary

As written by the sponsor on the registry.

A randomized, double-blind, placebo-controlled phase I clinical study evaluating the safety, tolerability, pharmacokinetics, pharmacodynamics, and immunogenicity of SLN12140 in healthy participants with single subcutaneous/intravenous dose escalation and multiple subcutaneous administrations

Conditions

  • Healthy Volunteer

Interventions

  • SLN12140Drug

    SLN12140 for sc injection or IV infusion

  • PlaceboOther

    Placebo for sc injection or IV infusion

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Safety and tolerability of SLN12140Time frame: 36 days

Locations

3 sites in 1 country. Site status is shown where the registry gives one.

  • Huashan Hospital

    Shanghai, Shanghai Municipality, China

  • Phase I center of Fudan University Huashan Hospital

    Shanghai, Shanghai Municipality, China

  • Huashan Hospital

    Shanghai, Shanghai Municipality, China

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.